Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer

[1]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[2]  G. Giannelli,et al.  Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. , 2005, Gastroenterology.

[3]  Katsunori Yoshida,et al.  Transforming growth factor-β and platelet-derived growth factor signal via c-jun N-terminal kinase- dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury , 2005 .

[4]  Katsunori Yoshida,et al.  Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. , 2005, The American journal of pathology.

[5]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[6]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[7]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[8]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[9]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[10]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[11]  B. Hock,et al.  Induction of Exosome Release in Primary B Cells Stimulated via CD40 and the IL-4 Receptor1 , 2008, The Journal of Immunology.

[12]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[13]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[14]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[15]  J. Rinn,et al.  Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells , 2010, Nature Genetics.

[16]  W. Ding,et al.  Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor‐β , 2010, Hepatology.

[17]  Jianren Gu,et al.  Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma , 2009, International journal of cancer.

[18]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[19]  Wen-Lang Lin,et al.  Intercellular nanovesicle‐mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth , 2011, Hepatology.

[20]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.

[21]  Yi-Wei Chen,et al.  Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. , 2011, Journal of neurosurgery.

[22]  M. Zern,et al.  Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. , 2011, Journal of hepatology.

[23]  T. Meyer,et al.  Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? , 2012, Journal of hepatology.

[24]  P. Brown,et al.  Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[25]  T. Patel,et al.  Non-coding RNAs as therapeutic targets in hepatocellular cancer. , 2012, Current cancer drug targets.

[26]  Hefen Sun,et al.  BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. , 2012, Cancer research.

[27]  Yuchang Li,et al.  Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial–mesenchymal transition in liver injury , 2013, Proceedings of the National Academy of Sciences.

[28]  T. Patel,et al.  Isolation of extracellular nanovesicle microRNA from liver cancer cells in culture. , 2013, Methods in molecular biology.

[29]  Stephanie Ma.  Biology and clinical implications of CD133(+) liver cancer stem cells. , 2013, Experimental cell research.

[30]  S. Friedman,et al.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.

[31]  X. Wang,et al.  Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma , 2013, Hepatology.

[32]  Y. Mo,et al.  The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage , 2012, Cell Research.